Cosmetic compositions comprising oligopeptides, tetrapeptides and hexapeptides

Abstract

Disclosed are cosmetic compositions comprising (a) an oligopeptide selected from the group consisting of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1, myristoyl oligopeptide-1, or combinations thereof; (b) a tetrapeptide selected from the group consisting of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, myristoyl tetrapeptide-9, or combinations thereof; and (c) a hexapeptide selected from the group consisting of hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11, myristoyl hexapeptide-11, or combinations thereof.

Description

Technical Field

[0001] This invention relates to cosmetic compositions comprising oligopeptides, tetrapeptides, and hexapeptides, said cosmetic compositions for providing enhanced anti-aging benefits. Background Technology

[0002] The skin is the body's primary barrier, protecting internal organs from external stimuli. Skin undergoes both internal and external aging. Skin aging is a complex process, and due to aging, changes in the skin differ from those in other organs. Characteristics of internal or temporal skin aging include dryness, visible free lines and wrinkles, uneven skin pigmentation, loss of elasticity, and sagging. External factors, including exposure to sunlight, pollutants, and cigarette smoke, can accelerate the skin aging process, particularly on the face.

[0003] One of the main causes of skin aging is the degradation of collagen and elastin, which are major components of the extracellular matrix that provides structural support and mechanical strength to the skin. Lumican is a small, leucine-rich proteoglycan involved in the regulation of collagen fibrillation and the organization of the extracellular matrix. Matrix metalloproteinases are proteases capable of dissolving peptide bonds and thus degrading collagen. Upregulating the expression of lumican genes, promoting collagen production, or reducing matrix metalloproteinases typically leads to enhanced anti-aging benefits.

[0004] Therefore, the inventors have recognized the need for further development of solutions to combat aging by upregulating the expression of photoglucan genes, promoting collagen production, and / or reducing matrix metalloproteinases. Surprisingly, it has been found that improved anti-aging benefits can be provided by including oligopeptides, tetrapeptides, and hexapeptides in the cosmetic compositions of the present invention. Summary of the Invention

[0005] In a first aspect, the present invention relates to a cosmetic composition comprising (a) an oligopeptide selected from oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1, myristoyl oligopeptide-1, or combinations thereof; (b) a tetrapeptide selected from tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, myristoyl tetrapeptide-9, or combinations thereof; and (c) a hexapeptide selected from hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11, myristoyl hexapeptide-11, or combinations thereof.

[0006] In a second aspect, the present invention relates to a method for providing benefits selected from enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging, skin rejuvenation, and upregulating the expression of photoglycan genes, or combinations thereof, the method comprising the step of applying the composition of the invention to a desired surface.

[0007] In a third aspect, the present invention relates to the use of the cosmetic compositions of the present invention for providing benefits selected from enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging, skin restoration, and upregulating the expression of photoglucan genes.

[0008] All other aspects of the invention will become more readily apparent upon consideration of the following detailed description and embodiments. Detailed Implementation

[0009] Except as expressly indicated in the examples or otherwise, all numerical values ​​indicating the amount of material or reaction conditions, physical properties of the material and / or uses in this specification may optionally be understood to be modified by “about”.

[0010] Unless otherwise specified, all quantities are by weight of the composition.

[0011] It should be noted that when specifying any numerical range, any particular upper limit value can be associated with any particular lower limit value.

[0012] To avoid ambiguity, the word "contains" is intended to mean "including" but not necessarily "composed of" or "consisting of". In other words, the steps or options listed do not have to be exhaustive.

[0013] The disclosure of the invention found herein should be considered to cover all embodiments found in claims that are multi-dependent on each other, regardless of the fact that the claims may be found not to be multi-dependent or to be redundant.

[0014] Where features are disclosed with respect to a particular aspect of the invention (e.g., the compositions of the invention), such disclosure should be considered applicable to any other aspect of the invention (e.g., the methods of the invention) after necessary modifications.

[0015] Preferably, the total amount of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1 and myristoyl oligopeptide-1 is 0.000001% to 1% by weight, more preferably 0.000004% to 0.5% by weight, even more preferably 0.00001% to 0.2% by weight, even more preferably 0.00006% to 0.05% by weight, and most preferably 0.0003% to 0.01% by weight.

[0016] Preferably, the total amount of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9 and myristoyl tetrapeptide-9 is 0.000001% to 1% by weight, more preferably 0.0000003% to 0.5% by weight, even more preferably 0.00001% to 0.2% by weight, even more preferably 0.00005% to 0.04% by weight, and most preferably 0.00015% to 0.008% by weight.

[0017] Preferably, the total amount of hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11 and myristoyl hexapeptide-11 is 0.000001% to 1% by weight, more preferably 0.000003% to 0.5% by weight, even more preferably 0.00001% to 0.2% by weight, even more preferably 0.00005% to 0.04% by weight, and most preferably 0.0002% to 0.008% by weight.

[0018] Preferably, the total weight ratio of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1, and myristoyl oligopeptide-1 to the total weight ratio of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, and myristoyl tetrapeptide-9 is 1:100 to 100:1, more preferably 1:30 to 30:1, even more preferably 1:10 to 10:1, and even more preferably 1:3 to 3:1. Preferably, the total weight ratio of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1, and myristoyl oligopeptide-1 to the total weight ratio of hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11, and myristoyl hexapeptide-11 is 1:100 to 100:1, more preferably 1:30 to 30:1, even more preferably 1:10 to 10:1, and even more preferably 1:3 to 3:1.

[0019] Preferably, the total amount of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9 and myristoyl tetrapeptide-9 is in a weight ratio of 1:100 to 100:1 to the total amount of hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11 and myristoyl hexapeptide-11 to 1:100, more preferably 1:30 to 30:1, even more preferably 1:10 to 10:1, and even more preferably 1:3 to 3:1.

[0020] Alternatively, the weight ratio of the total amount of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1, and myristoyl oligopeptide-1 to the total amount of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, and myristoyl tetrapeptide-9 is preferably 1:30 to 300:1, more preferably 1:10 to 100:1, even more preferably 1:3 to 30:1, and even more preferably 1:1 to 12:1. Preferably, the weight ratio of the total amount of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1, and myristoyl oligopeptide-1 to the total amount of hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11, and myristoyl hexapeptide-11 is 1:25 to 200:1, more preferably 1:12 to 90:1, even more preferably 1:4 to 30:1, and even more preferably 1:1 to 9:1. Preferably, the total weight ratio of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9 and myristoyl tetrapeptide-9 to the total weight ratio of hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11 and myristoyl hexapeptide-11 is 1:135 to 54:1, more preferably 1:45 to 18:1, even more preferably 1:15 to 6:1, and even more preferably 1:5 to 2:1.

[0021] Preferably, the present invention provides a cosmetic composition comprising oligopeptide-1, acetyl tetrapeptide-9, and hexapeptide-11.

[0022] Preferably, the amount of oligopeptide-1 is 0.000001% to 1% by weight, more preferably 0.000004% to 0.5% by weight, even more preferably 0.00001% to 0.2% by weight, even more preferably 0.00006% to 0.05% by weight, and most preferably 0.0003% to 0.01% by weight, based on the total amount of the composition. Preferably, the amount of acetyl tetrapeptide-9 is 0.000001% to 1% by weight, more preferably 0.0000003% to 0.5% by weight, even more preferably 0.00001% to 0.2% by weight, even more preferably 0.00005% to 0.04% by weight, and most preferably 0.00015% to 0.008% by weight, based on the total amount of the composition. Preferably, the amount of hexapeptide-11 is 0.000001% to 1% by weight based on the total amount of the composition, more preferably 0.000003% to 0.5% by weight, even more preferably 0.00001% to 0.2% by weight, even more preferably 0.00005% to 0.04% by weight, and most preferably 0.0002% to 0.008% by weight.

[0023] Preferably, the weight ratio of oligopeptide-1 to acetyl tetrapeptide-9 is 1:100 to 100:1, more preferably 1:30 to 30:1, even more preferably 1:10 to 10:1, and even more preferably 1:3 to 3:1. Preferably, the weight ratio of oligopeptide-1 to hexapeptide-11 is 1:100 to 100:1, more preferably 1:30 to 30:1, even more preferably 1:10 to 10:1, and even more preferably 1:3 to 3:1. Preferably, the weight ratio of acetyl tetrapeptide-9 to hexapeptide-11 is 1:100 to 100:1, more preferably 1:30 to 30:1, even more preferably 1:10 to 10:1, and even more preferably 1:3 to 3:1.

[0024] Alternatively, the weight ratio of oligopeptide-1 to acetyl tetrapeptide-9 is 1:30 to 300:1, more preferably 1:10 to 100:1, even more preferably 1:3 to 30:1, and even more preferably 1:1 to 12:1. Preferably, the weight ratio of oligopeptide-1 to hexapeptide-11 is 1:25 to 200:1, more preferably 1:12 to 90:1, even more preferably 1:4 to 30:1, and even more preferably 1:1 to 9:1. Preferably, the weight ratio of acetyl tetrapeptide-9 to hexapeptide-11 is 1:135 to 54:1, more preferably 1:45 to 18:1, even more preferably 1:15 to 6:1, and even more preferably 1:5 to 2:1.

[0025] The composition preferably comprises a non-soap cleaning surfactant. The non-soap cleaning surfactant may be selected from anionic surfactants, cationic surfactants, nonionic surfactants, amphoteric surfactants, and mixtures thereof. Preferred surfactant compounds that may be used are non-soap anionic surfactants, nonionic surfactants, amphoteric surfactants, or mixtures thereof.

[0026] Suitable non-soap anionic surfactants include linear alkylbenzene sulfonates, primary and secondary alkyl sulfates, especially C8 to C96 sulfates. 15 Primary alkyl sulfates; alkyl ether sulfates; olefin sulfonates; alkyl xylene sulfonates; dialkyl sulfosuccinates; fatty acid ester sulfonates; or mixtures thereof. Sodium salts are generally preferred. The most preferred non-soap anionic surfactants are linear alkylbenzene sulfonates, especially those having C8 to C96. 15 Linear alkylbenzene sulfonates with alkyl chain lengths. Preferably, the level of linear alkylbenzene sulfonates is from 0% to 30% by weight of the total composition, more preferably from 1% to 25% by weight, and most preferably from 2% to 15% by weight.

[0027] The nonionic surfactants that can be used include primary and secondary alcohol ethoxylates, particularly C8 to C9 ethoxylates with an average of 1 to 20 moles of ethylene oxide per mole of alcohol. 20 Aliphatic alcohols, and more particularly, alcohols ethoxylated with an average of 1 to 10 moles of ethylene oxide per mole. 10 To C 15 Primary and secondary aliphatic alcohols. Non-ethoxylated nonionic surfactants include alkyl polyglycosides, glycerol monoethers, and polyhydroxyamides (glucamide). Preferably, the level of the nonionic surfactant is from 0% to 30% by weight, more preferably from 1% to 25% by weight, and most preferably from 2% to 15% by weight, based on the weight of a fully formulated composition containing the microcapsules of the present invention.

[0028] Suitable amphoteric surfactants are preferably betaine surfactants. Examples of suitable amphoteric surfactants include, but are not limited to, alkyl betaines, alkylamide betaines, alkyl sulfobetaine, alkyl sulfobetaine, and alkylamide sulfobetaine; preferably, those having 8 to about 18 carbon atoms in the alkyl and acyl groups. Preferably, the amount of the amphoteric surfactant is 0 to 20% by weight of the composition, more preferably 1 to 10% by weight.

[0029] It may also contain specific monoalkyl cationic surfactants. Permissible cationic surfactants include: general formula R 1 R 2 R 3 R 4 N + X - A quaternary ammonium salt wherein R is a long or short hydrocarbon chain, typically alkyl, hydroxyalkyl, or ethoxylated alkyl, and X is a counterion (e.g., in the following compounds, where R is a long or short hydrocarbon chain). 1 C8-C 22 Alkyl groups, preferably C8-C 10 Or C 12 -C 14 Alkyl, R 2 It is methyl, and R 3 and R 4 They can be the same or different (methyl or hydroxyethyl); and cationic esters (e.g., choline esters).

[0030] The composition may contain 10 to 95% water by weight of the composition, more preferably 45 to 92%, even more preferably 52 to 90%, and most preferably 60% to 84%. Alternatively, the composition may contain 35 to 99% water by weight of the composition, more preferably 50 to 99%, even more preferably 70 to 97%, and most preferably 80% to 95%.

[0031] The composition may contain a resorcinol derivative. A resorcinol derivative preferably means that at least one hydrogen atom on the ring structure and / or hydroxyl group of resorcinol is substituted with an alkyl or phenylalkyl group. Preferably, the resorcinol derivative is a 4-substituted resorcinol. Preferably, the resorcinol derivative is selected from 4-ethylresorcinol, 4-butylresorcinol, 4-hexylresorcinol, phenylethylresorcinol, or mixtures thereof, more preferably, the resorcinol derivative comprises 4-hexylresorcinol. The amount of the resorcinol derivative is preferably in the range of 0.00001 to 10% based on the total amount of the composition, more preferably 0.001 to 5%, and most preferably 0.1 to 0.6%.

[0032] Preferably, the composition comprises a vitamin B3 compound (including derivatives of vitamin B3). The vitamin B3 compound comprises niacin, nicotinic acid, nicotinamide, or mixtures thereof. The most preferred vitamin B3 compound is nicotinamide. The amount of the vitamin B3 compound may be from 0.1% to 10% by weight of the composition, preferably from 0.5% to 5%.

[0033] The composition preferably additionally comprises one or more organic sunscreens. A variety of organic sunscreens are suitable for use in combination with the essential ingredients of this invention. Suitable UV-A / UV-B sunscreens include 2-hydroxy-4-methoxybenzophenone, octyl dimethyl para-aminobenzoic acid, digalloyltrioleate, 2,2-dihydroxy-4-methoxybenzophenone, ethyl-4-(di(hydroxypropyl))aminobenzoate, 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, 2-ethylhexyl salicylate, glyceryl para-aminobenzoate, 3,3,5-trimethylcyclohexyl salicylate, methyl anthranilate, p-dimethylaminobenzoic acid or aminobenzoate, 2-ethylhexyl-p-dimethylaminobenzoate, 2-phenylbenzimidazole-5-sulfonic acid, 2-(p-dimethylaminophenyl)-5-sulfonic benzoxazoic acid (2-(p-dimethylaminophenyl)-5-sulfonic benzoxazoic acid) Organic sunscreens include 2-ethylhexyl-p-methoxycinnamate, butyl methoxydibenzoylmethane, 2-hydroxy-4-methoxybenzophenone, octyl dimethyl-p-aminobenzoic acid, and mixtures thereof. The most suitable organic sunscreens are 2-ethylhexyl-p-methoxycinnamate, butyl methoxydibenzoylmethane, or mixtures thereof. Safe and effective amounts of organic sunscreens can be used in compositions applicable to the subject matter of this invention. The compositions preferably contain 0.1% to 10%, more preferably 0.1% to 5% of an organic sunscreen by weight of the composition.

[0034] Preferably, the composition comprises a polyol. The polyol may be selected from glycerol, propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexanediol, 1,3-butanediol, isopentyl glycol, ethoxylated glycerol, propoxylated glycerol, or mixtures thereof. The most preferred polyol is glycerol, and glycerol is also known. The amount of the polyol may be in any range from 0.1% to 20% by weight of the composition, preferably from 0.5% to 15%, more preferably 2% and 10%.

[0035] Water-insoluble skin-beneficial agents can also be formulated into the composition as conditioning and moisturizing agents. Examples include silicone oils; and vegetable triglycerides, such as sunflower seed oil and cottonseed oil.

[0036] Some compositions may contain thickeners. These thickeners may be selected from, but are not limited to, cellulosics, natural gums, and acrylic polymers. Cellulosics include sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, and combinations thereof. Suitable gums include xanthan gum, pectin, ebony gum, agar, alginate gum, and combinations thereof. Acrylic thickeners include homopolymers and copolymers of acrylic acid and methacrylic acid, including carbomers, such as Carbopol 1382, Carbopol 982, Ultrez, Aqua SF-1, and Aqua SF-2, available from Lubrizol Corporation. The amount of thickener may range from 0.01% to 3% by weight of the active polymer (other than solvent or water) in the composition.

[0037] Preservatives can be desiccated into the compositions of the present invention to prevent the growth of potentially harmful microorganisms. Suitable conventional preservatives for use in the compositions of the present invention are alkyl esters of hydrobenzoic acid. Other preservatives recently put into use include hydantoin derivatives, propionates, and various quaternary ammonium compounds. Particularly preferred preservatives are phenoxyethanol, methylparaben, propylparaben, imidazolidinyl urea, sodium dehydroacetate, and benzyl alcohol. The preservative should be selected according to the intended use of the composition and possible incompatibilities between the preservative and other components. The preservative is preferably used in an amount of 0.01% to 2% by weight of the composition.

[0038] A variety of other optional materials may be formulated into the composition. These materials may include: antimicrobial agents, such as 2-hydroxy-4,2',4'-trichlorodiphenyl ether (triclosan), 2,6-dimethyl-4-hydroxychlorobenzene, and 3,4,4'-trichlorocarbonylaniline; scrubbing and exfoliating particles, such as polyethylene and silica or alumina; cooling agents, such as menthol; skin soothing agents, such as aloe vera; and colorants.

[0039] Furthermore, the compositions of the present invention may further comprise 0.5 to 10% by weight of a chelating agent, such as tetrasodium ethylenediaminetetraacetate (EDTA), EHDP, or mixtures thereof; an opacifier and a pearlescent agent, such as ethylene glycol distearate, titanium dioxide, or Lytron 621 (styrene / acrylate copolymer); all of which may be used to enhance the appearance or properties of the product.

[0040] The viscosity of the composition is preferably from 1 to 500 Pa·s, more preferably from 5 to 150 Pa·s, even more preferably from 10 to 60 Pa·s, and most preferably from 20 to 40 Pa·s. Viscosity used herein is expressed in terms of 10 s⁻¹. -1The shear rate was measured at 25°C using a rheometer system (Anton Paar Rheometer MCR501, Austria) with sandblasted parallel plates (PP50) and a plate-to-plate spacing of 0.5 mm. Preferably, the composition is an emulsion, more preferably an oil-in-water emulsion. Preferably, the composition is a fluid liquid at 25°C and atmospheric pressure.

[0041] Preferably, the cosmetic composition is a skin care composition. A skin care composition refers to a composition suitable for topical application to human skin, including leave-on and wash-off products, but preferably leave-on compositions. The term "leave-on" as used herein refers to a composition applied to or smeared on the skin and left thereon. The term "wash-off" as used herein refers to a skin cleanser applied to or smeared on the skin and rinsed off substantially immediately after application. The term "skin" as used herein includes the skin on the face, neck, chest, abdomen, back, arms, armpits, hands, and legs. Preferably, "skin" means skin including the face and armpits; more preferably, skin means skin on the face excluding the lips. The composition is particularly preferably a moisturizer rather than a makeup product.

[0042] Preferably, the composition is a topical composition. Preferably, the composition may be in the form of a cream, lotion, ointment, solution, suspension, toner, emulsion, paste, gel, powder, powder foundation, lotion foundation, wax foundation, or spray. More preferably, the composition may be formulated as a cream, emulsion, ointment, lotion, gel, or spray.

[0043] Preferably, the use is non-therapeutic. Preferably, the method is non-therapeutic. The term "non-therapeutic" generally means for cosmetic purposes rather than for curative or therapeutic purposes.

[0044] The following embodiments are provided to aid in understanding the invention. These embodiments are not intended to limit the scope of the claims.

[0045] Example Example 1 This embodiment demonstrates that the peptide combination according to the present invention upregulates the expression of the photoprotein glycan gene.

[0046] The gene expression of optical proteoglycans in different samples was evaluated according to the following procedure. L929 fibroblasts in good growth condition during the logarithmic growth phase were used, with a concentration of 1×10⁻⁶ cells / cells. 4Cells were seeded at a density of 10 cells / well in 48-well plates and incubated overnight at 37°C with 5% CO2. Cells were treated for 24 hours according to Table 1. After treatment, total RNA was extracted from each sample using the RNAprep PurePlant Plus Kit (DP441, Tiangen) according to the manufacturer's instructions.

[0047] Extracted RNA was reverse transcribed to generate template cDNA using the PrimeScript kit. Target genes were amplified using the appropriate primers on an ABI Vii 7 real-time PCR system (Applied Biosystems, Thermo Fisher Scientific, Carlsbad, CA, USA) with Hieff™ qPCRSYBR Green Master Mix. The relative quantification of gene expression was calculated using the comparative Ct method. All samples were first normalized to the housekeeping gene GAPDH, and then normalized again to their corresponding controls to obtain ΔΔCt values. The fold change relative to this control (2^(-ΔΔCt)) was calculated and compared between treatments. All tests were performed at least three times, and Table 1 shows the fold change in gene expression of the optical proteoglycan.

[0048] Table 1

[0049] The level of active ingredient is expressed as a weight percentage based on the amount of culture medium.

[0050] a: WKPep ® Soligopeptide-PLUS, purchased from Winkey Technology in China.

[0051] b: WKPep ® D-tide, purchased from Winkey Technology in China.

[0052] c: WKPep ® Rpeptide, purchased from Winkey Technology in China.

[0053] As demonstrated in Table 1, the fold change of 1 was significantly higher than the product of the fold changes of samples A, B, and C. Therefore, it was unexpected that the combination of oligopeptide-1, acetyl tetrapeptide-9, and hexapeptide-11 significantly upregulated the expression of photoglucan genes, thus providing anti-aging-related benefits.

[0054] Example 2 This embodiment demonstrates the reduction of matrix metalloproteinase 1 (MMP1) through the peptide combination of the present invention.

[0055] The inhibition of MMP1 expression was tested using the following procedure. Human fibroblasts in the exponential growth phase (Kunming Cell Bank, Chinese Academy of Sciences) were taken and digested with 0.25% (w / w) trypsin solution to detach the adherent cells. Cells cultured in PBS were then exposed to UVB (80 mJ / cm²). 2 Irradiate for 15 minutes, then incubate for 48 hours in medium containing or without the active ingredient, according to Table 2. After incubation, MMP1 levels were obtained using the MMP-1 ELISA kit (IEBO, catalog number: E0097h) according to the manufacturer's instructions. The fold reduction was calculated by (Level of MMP1 for control / Level of MMP1 for control) . Each test was repeated three times, and the results are shown in Table 2.

[0056] Table 2

[0057] The level of active ingredient is expressed as a weight percentage based on the amount of culture medium.

[0058] As shown in Table 2, when the three peptides are combined, the reduction fold of MMP1 (Sample 2) is higher than the product of the reduction folds of the three individual peptides (G, H, and I), or the product of the reduction folds of any two peptide combinations and the third individual peptide (J and I, or K and H, or L and G). It was unexpectedly found that the peptide combinations of the present invention provide synergistically better inhibition of MMP1, thus providing anti-aging benefits.

Claims

1. A cosmetic composition comprising: (a) an oligopeptide, wherein the oligopeptide is selected from oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1, myristoyl oligopeptide-1, or a combination thereof; (b) a tetrapeptide, said tetrapeptide being selected from tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, myristoyl tetrapeptide-9, or combinations thereof; and (c) A hexapeptide, wherein the hexapeptide is selected from hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11, myristoyl hexapeptide-11, or combinations thereof. The total weight ratio of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9 and myristoyl tetrapeptide-9 to the total weight ratio of hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11 and myristoyl hexapeptide-11 is 1:100 to 100:

1.

2. The composition according to claim 1, wherein the total amount of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1 and myristoyl oligopeptide-1 is from 0.000001% by weight to 1% by weight, preferably from 0.0001% by weight to 0.1% by weight, based on the total amount of the composition.

3. The composition according to claim 1 or 2, wherein the total amount of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9 and myristoyl tetrapeptide-9 is from 0.000001% by weight to 1% by weight, preferably from 0.0001% by weight to 0.1% by weight, based on the total amount of the composition.

4. The composition according to any one of the preceding claims, wherein the total amount of hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11 and myristoyl hexapeptide-11 is from 0.000001% by weight to 1% by weight, preferably from 0.0001% by weight to 0.1% by weight, based on the total amount of the composition.

5. The composition according to any one of the preceding claims, wherein the total amount of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1 and myristoyl oligopeptide-1 is in a weight ratio of 1:100 to 100:1, preferably 1:10 to 10:

1.

6. The composition according to any one of the preceding claims, wherein the total amount of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1 and myristoyl oligopeptide-1 is in a weight ratio of 1:100 to 100:1, preferably 1:10 to 10:

1.

7. A cosmetic composition comprising oligopeptide-1, acetyl tetrapeptide-9 and hexapeptide-11.

8. The composition according to any one of the preceding claims, wherein the amount of oligopeptide-1 is from 0.000001% by weight to 1% by weight, preferably from 0.00006% by weight to 0.05% by weight, based on the total amount of the composition.

9. The composition according to any one of the preceding claims, wherein the amount of acetyl tetrapeptide-9 is from 0.000001% by weight to 1% by weight, preferably from 0.00005% by weight to 0.04% by weight, based on the total amount of the composition.

10. The composition according to any one of the preceding claims, wherein the amount of hexapeptide-11 is from 0.000001% by weight to 1% by weight, preferably from 0.00005% by weight to 0.04% by weight, based on the total amount of the composition.

11. The composition according to any one of the preceding claims, wherein the weight ratio of oligopeptide-1 to acetyl tetrapeptide-9 is 1:30 to 300:1, preferably 1:3 to 30:

1.

12. The composition according to any one of the preceding claims, wherein the weight ratio of oligopeptide-1 to hexapeptide-11 is 1:25 to 200:1, more preferably 1:4 to 30:

1.

13. The composition according to any one of the preceding claims, wherein the composition is an emulsion, preferably an oil-in-water emulsion.

14. A method of providing benefits selected from enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging, skin rejuvenation, and upregulating the expression of photoglycan genes, or combinations thereof, the method comprising the step of applying the composition according to any one of claims 1 to 13 to a desired surface.

15. Use of the cosmetic composition according to any one of claims 1 to 13 for providing benefits selected from enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging, skin restoration, and upregulating the expression of photoglycan genes.

Images